Clinical trials
Relapsed clinical trials
Below are recruiting relapsed clinical trials, each written for real people, not researchers. We’re tracking 892 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06796504Recruiting
Nerve stimulation for relapsing-remitting multiple sclerosis
This trial tests a device that stimulates a nerve in the neck, which may help repair the protective coating around nerves in the brain and spinal cord. It is for people with relapsing-remitting MS who are stable on their current medication and have some vision problems due to MS.
Irvine, CaliforniaAges 22–60 - NCT06799026RecruitingPhase 1
Vaccine plus elranatamab for advanced multiple myeloma
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) mixed with myeloma cells, given together with a drug called elranatamab. It is for people with multiple myeloma that has not responded to at least three prior treatments.
Boston, MassachusettsAges 18 years+ - NCT06789159RecruitingPhase 1
VK-2019 for relapsed/refractory EBV-positive DLBCL
This trial tests a new drug called VK-2019 for people whose EBV-positive diffuse large B-cell lymphoma has come back or not responded to at least two prior treatments. The goal is to see if this drug can shrink tumors and help control the cancer.
Lexington, KentuckyAges 18 years+ - NCT06651853RecruitingPhase 2
Radiation therapy with lenalidomide and glofitamab for DLBCL
This trial tests a combination of radiation therapy, lenalidomide, and glofitamab for people with a type of lymphoma called DLBCL that has not responded to or has returned after initial treatment. The goal is to see if this combination can help when other treatments have failed.
Xiamen, FujianAges 18 years+ - NCT06755450RecruitingPhase 1
Study of AUR112 for advanced lymphoma or CLL
This trial tests a new oral medication called AUR112 for people with advanced lymphoma or CLL that has not responded to at least 2 prior treatments. The goal is to see if it is safe and how it works in the body.
Vadodara, GujaratAges 18–99 - NCT06718634RecruitingPhase 1
Study of BL-M08D1 for returning blood cancers
This trial tests a new drug called BL-M08D1 for people with lymphoma or other blood cancers that came back or didn't respond to standard treatments. It aims to see if the drug can help when other options are no longer working.
Harbin, HeilongjiangAges 18–75 - NCT04684147RecruitingPhase 2
CNCT19 cell therapy for relapsed or refractory ALL
This Phase 2 study tests an infusion of modified immune cells (CNCT19) in people with acute lymphoblastic leukemia (ALL) that has come back or did not respond to treatment. It may help by targeting leukemia cells that have a specific marker called CD19.
Beijing, Beijing MunicipalityAges 18–65 - NCT06703892RecruitingPhase 1
CAR T-cell therapy for relapsed B-cell lymphoma
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
TaipeiAges 18–70 - NCT03672721RecruitingPhase 1/Phase 2
Carboplatin with radiation for returning glioblastoma
This Phase 1/2 study tests a combination of carboplatin chemotherapy with radiation for glioblastoma that has come back. It aims to shrink or control the tumor after standard treatment has already been used.
Sherbrooke, QuebecAges 18 years+ - NCT06681220RecruitingPhase 1/Phase 2
Temozolomide and stenoparib for relapsed small cell lung cancer
This trial tests two drugs—temozolomide and stenoparib—for people with small cell lung cancer that has returned after initial chemo. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Palo Alto, CaliforniaAges 18 years+ - NCT05565807RecruitingPhase 1/Phase 2
Study drug for difficult myeloma after prior treatments
This trial tests an anti-CD38 antibody drug that is “linked” to a cancer-killing payload (an antibody-drug conjugate) in people with multiple myeloma that has returned or did not respond to standard treatments. It is mainly looking at safety first, and also whether it can reduce myeloma in heavily pre-treated patients.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06645678RecruitingPhase 1/Phase 2
Mezigdomide and Elranatamab for relapsed or hard-to-treat multiple myeloma
This trial tests two drugs, mezigdomide (a pill) and elranatamab (an injection), in people whose multiple myeloma has come back or not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
SingaporeAges 19 years+ - NCT06634589RecruitingPhase 1/Phase 2
Combination therapy for relapsed B-cell blood cancers
This study tests new drug combinations for people with B-cell blood cancers (like lymphoma or leukemia) that have come back or stopped responding to treatment. It aims to see if these combos are safe and can help fight the cancer.
Phoenix, ArizonaAges 18 years+ - NCT06641648RecruitingPhase 1
Donor NK cells with low-dose IL-2 for AML relapse after stem cell transplant
This trial tests a new treatment for patients whose acute myeloid leukemia (AML) has come back after a stem cell transplant. It uses immune cells from the original donor, combined with a low dose of a protein called IL-2, to try to fight the leukemia without causing severe side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06644183RecruitingPhase 1/Phase 2
Triple therapy for relapsed CLL after prior treatments
This trial tests three drugs—roginolisib, venetoclax, and rituximab—for people with CLL that has come back or not responded after at least two prior treatments, including a BTK inhibitor. The goal is to see if this combination is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT04598399Recruiting
Mindfulness program for alcohol relapse prevention
This study compares two non-medication programs to help people with alcohol use disorder stay away from relapse. It tests whether mindfulness-based relapse prevention works better than relaxation meditation without a guide.
AngersAges 18 years+ - NCT06615479RecruitingPhase 3
New treatment vs standard care for relapsed multiple myeloma
This trial tests a new treatment called BMS-986393 (a type of CAR T-cell therapy) compared to standard treatments for adults with multiple myeloma that has come back or is not responding to therapy, and who have already been treated with lenalidomide (Revlimid). The goal is to see if the new treatment works better.
Birmingham, AlabamaAges 18 years+ - NCT03850574RecruitingPhase 1/Phase 2
Tuspetinib for relapsed or hard-to-treat AML
This early-phase study tests tuspetinib in people with AML that has come back or did not respond to treatment. The goal is to learn whether it is safe and tolerable, how the drug behaves in the body, and whether it shows signs of benefit.
Birmingham, AlabamaAges 18 years+ - NCT06599580Recruiting
Checking kids' arm measurements to prevent relapse after malnutrition recovery
This study tests whether measuring a caregiver's arm width can help predict if a child who recently recovered from severe malnutrition will become malnourished again. It aims to find ways to catch problems early and keep children healthy.
NounaAges 6 months–4.5 years - NCT06574568RecruitingPhase 1
Study of YKST02 for relapsed or refractory multiple myeloma
This study tests a new drug called YKST02 for people with multiple myeloma that has come back or hasn't responded to other treatments. The goal is to see if it can help when other therapies have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT06552416RecruitingPhase 1
Safety study of MT-401-OTS for relapsed AML or MDS
This trial tests a new cell therapy called MT-401-OTS for people aged 65 or older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The goal is to see if this treatment is safe and to find the right dose.
Duarte, CaliforniaAges 65 years+ - NCT06553053Recruiting
Acupuncture to prevent Crohn's disease relapse
This trial tests if acupuncture can help people with Crohn's disease stay in remission longer and avoid flare-ups. If you are in remission but have had frequent relapses, this study may be for you.
ShanghaiAges 16–75 - NCT06561152RecruitingPhase 1/Phase 2
Tagraxofusp plus low-intensity chemo for CD123+ AML
This trial tests a drug called tagraxofusp combined with a gentle chemotherapy regimen for people whose acute myeloid leukemia (AML) has come back or not responded to an initial venetoclax-based treatment. The study focuses on patients whose leukemia cells have a protein called CD123 on their surface.
Palo Alto, CaliforniaAges 18 years+ - NCT06160843RecruitingPhase 2
Pembrolizumab and olaparib for relapsed peripheral T-cell lymphoma
This trial tests whether combining two targeted drugs, pembrolizumab and olaparib, can help people with peripheral T-cell lymphoma that has come back or not responded to previous treatment. The goal is to find a new option for this type of cancer.
SingaporeAges 21–99
Hear when a new Relapsed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed?
- Yes. Clin2 currently lists 892 recruiting relapsed studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.